Irinotecan and Epirubicin for recurring bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two chemotherapy drugs (irinotecan and epirubicin) for people whose bladder cancer has come back after prior treatment with a similar drug. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bladder cancer that hasn't spread into the muscle layer of the bladder wall (non-muscle invasive).
- Your cancer came back after you were treated with a drug called an anthracycline (like doxorubicin or epirubicin).
- You have not had chemotherapy for any other cancer that goes through your whole body (systemic chemotherapy).
- Your cancer can be measured on scans using standard guidelines (RECIST).
- You are in good overall health, able to take care of yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This trial tests a new combination treatment for people with advanced colorectal cancer whose cancer has stopped responding to irinotecan. The goal is to see if adding a liposome form of irinotecan to other drugs can help shrink tumors or slow the disease.
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests a new, precise way to use chemotherapy to remove low-risk, non-muscle-invasive bladder tumors before surgery. It may be an option for people with small, slow-growing tumors that haven't spread into the bladder muscle.
This trial tests a combination of two chemotherapy drugs, gemcitabine and carboplatin, for people whose bladder cancer has progressed after treatment with enfortumab vedotin plus pembrolizumab. The goal is to see if this chemo regimen can help control the cancer.
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
Hear when a new Non-Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.